Nyxoah SA, trading under the symbol NASDAQ:NYXH, is a medical technology company that focuses on developing innovative treatments for Obstructive Sleep Apnea (OSA). The company is known for its Genio® system, which recently received FDA approval for treating moderate to severe OSA in adults. This approval is a significant milestone for Nyxoah, potentially boosting its market presence.
On August 18, 2025, NYXH is set to release its quarterly earnings. Wall Street anticipates an earnings per share (EPS) of -$0.63, with projected revenue of approximately $1.46 million. Nyxoah's preliminary results for the second quarter of 2025 show an anticipated revenue of €1.3 million, a 73% increase from the same period in 2024, as highlighted by the company's announcement.
Despite the revenue growth, Nyxoah faces financial challenges. The company has a negative price-to-earnings (P/E) ratio of -2.95, indicating ongoing losses. Its price-to-sales ratio is 47.18, meaning investors pay $47.18 for every dollar of sales. The enterprise value to sales ratio is similar at 47.11, reflecting the company's current valuation.
Nyxoah's financial difficulties are further highlighted by a negative enterprise value to operating cash flow ratio of -3.71 and a negative earnings yield of -33.86%. These figures suggest challenges in generating positive cash flow and earnings. However, the company maintains a low debt-to-equity ratio of 0.24, indicating conservative debt usage.
Additionally, Nyxoah's current ratio of 3.59 suggests strong liquidity, allowing the company to cover its short-term liabilities effectively. This financial stability, combined with the recent FDA approval, positions Nyxoah for potential growth despite its current financial hurdles.
